SamChunDang Pharm. Co., Ltd. is a leading Korean pharmaceutical company specialising in ophthalmic products and dedicated to developing high-quality generics and biosimilars. Renowned for its US and EU GMP certifications, SCD excels in the production of generic ophthalmic medications. Among its significant achievements is the development of a biosimilar for Eylea (Aflibercept), a notable treatment for macular degeneration, which has garnered industry recognition. SCD’s vision extends beyond ophthalmology, as the company is making strides in non-ophthalmic fields, including innovative drug delivery systems, oral GLP-1 therapies, and long-acting injections, with the aim of revolutionising the global pharmaceutical landscape.

Services include:
– Biologics
– Finished Dosage Forms
– Innovative Drug Delivery Systems
– Oral GLP-1
– Long-acting Injections

With a commitment to excellence and a focus on expanding its offerings, SamChunDang Pharm. Co., Ltd. continues to play a pivotal role in advancing pharmaceutical solutions. For more information, please visit scd.co.kr.